| Trial ID: | L5326 |
| Source ID: | NCT01114542
|
| Associated Drug: |
Insulin Degludec
|
| Title: |
A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: insulin degludec|DRUG: insulin glargine
|
| Outcome Measures: |
Primary: Area under the glucose infusion rate curve during one dosing interval of Insulin Degludec at steady state, 0-24 hours after dosing on day 8 | Secondary: Area under the glucose infusion rate curve during one dosing interval of insulin glargine at steady state, 0-24 hours after dosing on day 8|Area under the concentration-time curve during one dosing interval at steady state for Insulin Degludec, 0-24 hours after dosing on day 8|Area under the concentration-time curve during one dosing interval at steady state for insulin glargine, 0-24 hours after dosing on day 8
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
66
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-05-03
|
| Completion Date: |
2010-08-10
|
| Results First Posted: |
|
| Last Update Posted: |
2017-10-09
|
| Locations: |
Novo Nordisk Investigational Site, Neuss, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01114542
|
